BR112019023632A2 - uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor - Google Patents
uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor Download PDFInfo
- Publication number
- BR112019023632A2 BR112019023632A2 BR112019023632-5A BR112019023632A BR112019023632A2 BR 112019023632 A2 BR112019023632 A2 BR 112019023632A2 BR 112019023632 A BR112019023632 A BR 112019023632A BR 112019023632 A2 BR112019023632 A2 BR 112019023632A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- inhibitor
- alkyl
- heterocyclyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710350614.6 | 2017-05-18 | ||
| CN201710350614 | 2017-05-18 | ||
| PCT/CN2018/087246 WO2018210296A1 (zh) | 2017-05-18 | 2018-05-17 | 一种ezh2抑制剂与btk抑制剂联合在制备***的药物中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023632A2 true BR112019023632A2 (pt) | 2020-08-18 |
Family
ID=64273344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023632-5A BR112019023632A2 (pt) | 2017-05-18 | 2018-05-17 | uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11065239B2 (ru) |
| EP (1) | EP3626239A4 (ru) |
| JP (1) | JP7125952B2 (ru) |
| KR (1) | KR102635949B1 (ru) |
| CN (1) | CN109937041B (ru) |
| AU (1) | AU2018269262B2 (ru) |
| BR (1) | BR112019023632A2 (ru) |
| CA (1) | CA3058241A1 (ru) |
| MX (1) | MX2019012938A (ru) |
| MY (1) | MY201580A (ru) |
| RU (1) | RU2762893C2 (ru) |
| TW (1) | TWI810185B (ru) |
| WO (1) | WO2018210296A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2728827C2 (ru) * | 2016-01-05 | 2020-07-31 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения |
| WO2020117052A2 (en) * | 2018-12-03 | 2020-06-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Ezh2- fgfr inhibition in cancer |
| CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
| CN110372562B (zh) * | 2019-07-09 | 2021-04-06 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的晶型及其制备方法 |
| TW202114670A (zh) * | 2019-09-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途 |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2013049770A2 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| KR20150141971A (ko) * | 2013-04-08 | 2015-12-21 | 파마싸이클릭스 엘엘씨 | 이브루티닙 병용 요법 |
| UA122822C2 (uk) * | 2013-04-08 | 2021-01-06 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| AU2014360078A1 (en) | 2013-12-06 | 2016-06-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP6528779B2 (ja) | 2014-03-25 | 2019-06-12 | 小野薬品工業株式会社 | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 |
| PL3166608T3 (pl) * | 2014-07-07 | 2019-07-31 | Jiangsu Hengrui Medicine Co., Ltd. | Związki aminopirydazynonowe jako inhibitory kinaz białkowych |
| WO2016014859A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
| RU2727198C2 (ru) | 2015-11-19 | 2020-07-21 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Производное бензофурана, способ его получения и его применение в медицине |
-
2018
- 2018-05-17 JP JP2019561276A patent/JP7125952B2/ja active Active
- 2018-05-17 US US16/611,969 patent/US11065239B2/en active Active
- 2018-05-17 EP EP18802340.2A patent/EP3626239A4/en active Pending
- 2018-05-17 TW TW107116782A patent/TWI810185B/zh active
- 2018-05-17 KR KR1020197035448A patent/KR102635949B1/ko active IP Right Grant
- 2018-05-17 RU RU2019138222A patent/RU2762893C2/ru active
- 2018-05-17 CN CN201880004347.XA patent/CN109937041B/zh active Active
- 2018-05-17 CA CA3058241A patent/CA3058241A1/en active Pending
- 2018-05-17 MY MYPI2019006504A patent/MY201580A/en unknown
- 2018-05-17 AU AU2018269262A patent/AU2018269262B2/en active Active
- 2018-05-17 WO PCT/CN2018/087246 patent/WO2018210296A1/zh active Application Filing
- 2018-05-17 BR BR112019023632-5A patent/BR112019023632A2/pt unknown
- 2018-05-17 MX MX2019012938A patent/MX2019012938A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109937041B (zh) | 2022-04-12 |
| JP2020519588A (ja) | 2020-07-02 |
| RU2019138222A (ru) | 2021-06-18 |
| TWI810185B (zh) | 2023-08-01 |
| US11065239B2 (en) | 2021-07-20 |
| MY201580A (en) | 2024-03-02 |
| KR102635949B1 (ko) | 2024-02-14 |
| RU2019138222A3 (ru) | 2021-07-30 |
| MX2019012938A (es) | 2019-12-16 |
| AU2018269262B2 (en) | 2021-12-02 |
| WO2018210296A1 (zh) | 2018-11-22 |
| JP7125952B2 (ja) | 2022-08-25 |
| EP3626239A1 (en) | 2020-03-25 |
| US20210030736A1 (en) | 2021-02-04 |
| AU2018269262A1 (en) | 2019-10-31 |
| TW201900171A (zh) | 2019-01-01 |
| EP3626239A4 (en) | 2021-03-10 |
| RU2762893C2 (ru) | 2021-12-23 |
| CA3058241A1 (en) | 2018-11-22 |
| KR20200007851A (ko) | 2020-01-22 |
| CN109937041A (zh) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019023632A2 (pt) | uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor | |
| JP7476380B2 (ja) | 血液学的障害を治療するための化合物および組成物 | |
| EP3600270B1 (en) | Compounds and compositions for treating hematological disorders | |
| KR20190133047A (ko) | Mor 작용제 및 kor 작용제를 함유하는 약학적 조성물, 및 그의 용도 | |
| BRPI0715745A2 (pt) | compostos e mÉtodos para inibir a interaÇço de proteÍnas bcl com parceiros ligantes | |
| CN109982701B (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| TW202019409A (zh) | Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用 | |
| CN114008028A (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
| EP4346765A2 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
| JP6349464B2 (ja) | 新規な４−（アリール）−Ｎ−（２−アルコキシチエノ［３，２−ｂ］ピラジン−３−イル）−ピペラジン−１−カルボキサミド誘導体及びその抗増殖効果 | |
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| JP7200453B2 (ja) | Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体 | |
| JP2023528170A (ja) | アルケニルピリミジン系化合物、その調製方法及び使用 | |
| CN114430681A (zh) | 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 | |
| CN112912078B (zh) | 用于治疗***受体阳性乳腺癌的组合疗法 | |
| CN117357650A (zh) | 包含sos1抑制剂的药物组合物 | |
| TW201922707A (zh) | 咖啡酸衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |